Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results‐Medicare analysis-Reference-Cited by-同舟云学术

Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results‐Medicare analysis

Published:2018-10-17 Issue:23 Volume:124 Page:4486-4494
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Xiang Michael¹^ORCID,Holsinger F. Christopher²,Colevas A. Dimitrios³,Chen Michelle M.²,Le Quynh‐Thu¹,Beadle Beth M.¹

Affiliation:

1. Department of Radiation Oncology Stanford University Stanford California United States

2. Department of Otolaryngology, Division of Head and Neck Surgery Stanford University Stanford California United States

3. Department of Medicine, Division of Oncology Stanford University Stanford California United States

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.31708

Reference32 articles.

1. Cancer statistics, 2017

2. Cetuximab: its unique place in head and neck cancer treatment;Specenier P;Biol Targets Ther,2013

3. Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy

4. Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma

5. An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis;Cellular Oncology;2024-06-18

2. Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis;2024-01-19

3. Editorial of Special Issue “Oral Cancer: From Pathophysiology to Novel Therapeutic Approaches”;Biomedicines;2023-10-11

4. Influence of the microbiome on radiotherapy-induced oral mucositis and its management: A comprehensive review;Oral Oncology;2023-09

5. Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer;Head & Neck;2023-07-13